

- C. 1994. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. *Sciences* 266:1870-1874.
- [81] Fields, B. A., Malchiodi, E. L., Li, H., Ysern, X., Stauffacher, C. V., Schlievert, P. M., Karjalainen, K. and Mariuzza, R. A. 1996. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. *Nat.* 384:188-192.
- [82] Lehnert, N. M., Allen, D. L., Allen, B. L., Catasti, P., Shiflett, P. R., Chen, M., Lehnert, B. E. and Gupta, G. 2001. Structure- based design of a bispecific receptor mimic that inhibits T cell responses to a superantigen. *Biochem.* 14:4222-4228.
- [83] Kappler, J., White, J., Konzona, H., Clements, J. and Marrack, P. 1994. Binding of a soluble alpha beta T-cell receptor to superantigen/major histocompatibility complex ligands. *Proc Nat Acad Sci USA.* 91:8462-8466.
- [84] Malchiodi, E. L., Eisenstein, E., Fields, B. A., Ohlendorf, D. H., Schlievert, P. M., Karjalainen, K. and Mariuzza, R. A. 1995. Superantigen binding to a T cell receptor beta chain of known three-dimensional structure. *J Exp Med.* 182:1833-1845.
- [85] Leder, L., Llera, A., Lavoie, P. M., Lebedeva, M. I., Li, H., Sekaly, R. P., Bohach, G. A., Gahr, P. J., Schlievert, P. M., Karjalainen, K. and Mariuzza, R. A. 1998. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II. *J Exp Med.* 187:823-833.
- [86] Shusta, E. V., Holler, P. D., Kieke, M. C., Kranz, D. M. and Wittrup, K. D. 2000. Directed evolution of a stable scaffold for T-cell receptor engineering. *Nat. Biotechnol.* 18:754-759.
- [87] Kieke, M. C., Sundberg, E., Shusta, E. V., Mariuzza, R. A., Wittrup, K. D. and Kranz, D. M. 2001. High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. *J Mol Biol* 307:1305-1315.
- [88] Reiser, H. and Staderker, M. J. 1996. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. *N Engl J Med.* 335:1369-1377.
- [89] Egen, J. G., Kuhns, M. S. and Allison, J. P. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. *Nat. Immunol.* 3:611-618.
- [90] Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K. and Ledbetter, J. A. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med.* 174:561-569.
- [91] Saha, b., Jaklic, B., Harlan, D. M., Gray, G. S., June, C. H. and Abe, R. 1996. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. *J Immunol.* 157:3869-3875.
- [92] Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. j., Weiner, R. S., Birkhofer, M. J., Warner, G. L., Berry, K. K., Linsley, P. S., Krueger, J. G., Ochs, H. D., Kelley, S. L. and Kang, S. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. *J Clin Invest.* 103:1243-1252.
- [93] Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S. and Krueger, J. G. 2000. Blockade of T lymphocyte costimulation with cytotoxic T lymphocytes-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells and endothelial cells. *J Exp Med.* 192:681-694.
- [94] Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M, Moore, K. W. and O'Garra, A. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. *J Immunol.* 146:3444-3451.
- [95] Perrin, G. Q., Johnson, H. M. and Subramaniam, P. S. 1999. Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle. *Blood* 93:208-216.
- [96] Krakauer, T. 1995b. Inhibition of toxic shock syndrome toxin-1-induced cytokine production T cell activation by interleukin-10, interleukin-4, and dexamethasone. *J Infect Dis.* 172:988-992.
- [97] Bean, A. G., Freiberg, R. A., Andrade, S., Menson, S. and Zlotnick, A. 1993. Interleukin-10 protects mice against staphylococcal enterotoxin B-induced lethal shock. *Infect Immun.* 61:4937-4939.
- [98] Collins, L. V., Eriksson, K., Ulrich, R. G. and Tarkowski, A. 2002. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. *Infect Immun.* 70:2282-2287.
- [99] Groux, H., Bigler, M., deVries, J. E. and Roncarolo, M. G. 1996. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4⁺ T cells. *J Exp Med.* 184:19-29.
- [100] Groux, H., Bigler, M., deVries, J. E. and Roncarolo, M. G. 1998. Inhibitory and stimulatory effects of IL-10 on human CD8⁺ T cells. *J Immunol.* 160:3188-3193.
- [101] Hale, M. L., Margolin, S. B., Krakauer, T., Roy, C. J. And Stiles, B. G. 2002. Pirfenidone blocks the *in vitro* and *in vivo* effects of staphylococcal enterotoxin B. *Infect Immun.* 70:2989-2994.
- [102] LeClaire, R. D., Kell, W., Bavari, S., Smith, T. J. and Hunt, R. E. 1996. Protective effects of niacinamide in staphylococcal enterotoxin B-induced toxicity. *Toxicol.* 107:69-81.
- [103] Krakauer, T. and Stiles, B. G. 1999. Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release. *Clin Diagn Lab Immunol.* 6:594-598.
- [104] Krakauer, T. 2002. The polyphenol chlorogenic acid inhibits staphylococcal enterotoxins-induced inflammatory cytokines and chemokines. *Immunopharmacol Immunotoxicol.* 24:113-119.
- [105] Krakauer, T. and Buckley, M. 2006. Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. *Antimicrob Agents Chemother.* 50:391-395.
- [106] Dohlsten, M., Lando, P. A., Bjork, P., Abrahmsen, L., Ohlsson, L., Lind, P. and Kalland, T., 1995. Immunotherapy of human colon cancer by antibody-targeted superantigens. *Cancer Immunol Immunother.* 41:162-168.
- [107] Dohlsten, M., Abrahmsen, L., Bjork, P., Lando, P. A., Hedlund, G., Forsberg, G., Brodin, T., Gascoigne, N.

R., Forberg, C. and Lind, P. 1994. Monoclonal antibody-superantigen fusion proteins: tumor specific agents for T-cell-based tumor therapy. *Proc Nat Acad Sci USA*. 91:8945-8949.

- [108] Holzer, U., Bethge, W., Krull, F., Ihle, J., Handgretinger, R., Reisfeld, R. A., Dohlsten, M., Kalland, T., Niethammer, D. and Dannecker, G. E. 1995. Superantigen staphylococcal enterotoxin A dependent and antibody targeted lysis of GD2 positive neuroblastoma cells. *Cancer Immunol Immunother*. 41:129-136.
- [109] Ihle, J., Holzer, U., Krull, F., Dohlsten, M., Kalland, T., Niethammer, D. And Dannecker, G. E., 1995.

Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. *Cancer Res*. 55:623-628.

Author Profile

Dr. Ranu Agrawal has done M.Sc. (Applied Biochemistry), Ph.D. (Biochemistry). She is working at the designation of

Dr DS Kothari Post Doctoral Fellow in Chaudhari Charan Singh University, Meerut, U.P. India




Figure 1: Interaction of conventional antigen and superantigen with MHC class II molecule and TCR.




Figure 2: Diagrammatic representation of the interactions of various kinases and related signaling molecules involved in staphylococcal enterotoxin-induced signal transduction cascade.